10-Q: Omeros Q3 2025: Novo Nordisk Deal Boosts Liquidity

Omeros Corporation reports Q3 2025 results, highlighting a significant deal with Novo Nordisk for zaltenibart and an extended PDUFA date for narsoplimab.

Summary

• Net loss for the three months ended September 30, 2025, was $30.9 million, and for the nine months ended September 30, 2025, was $89.8 million.
• Cash, cash equivalents, and short-term investments totaled $36.1 million as of September 30, 2025, down from $86.7 million at December 31, 2024.
• The company entered into an Asset Purchase and License Agreement (APLA) with Novo Nordisk Health Care AG for zaltenibart, expected to close in Q4 2025, which will provide $240.0 million in upfront cash.
• The APLA includes potential additional milestone payments of $410.0 million for development/approval and up to $1.3 billion for sales-based achievements, plus tiered royalties.
• The PDUFA target action date for the narsoplimab BLA in TA-TMA has been extended to December 26, 2025.
• A Marketing Authorization Application (MAA) for narsoplimab in TA-TMA was submitted in the European Union, with an opinion expected in mid-2026.
• The Phase 3 clinical development program for zaltenibart in PNH was temporarily paused to prioritize capital.
• Cash used in operations for the nine months ended September 30, 2025, was $76.3 million.
• The company raised $20.3 million net from a registered direct offering and $15.3 million net from an at-the-market (ATM) equity offering during the nine months ended September 30, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern without the anticipated Novo Nordisk transaction or other financing.

Sentiment

Score: 4

Explanation: While the Novo Nordisk deal provides a critical liquidity injection and validates the company's MASP-3 program, mitigating immediate 'going concern' risks, the PDUFA extension for narsoplimab, continued net losses, and the temporary pause of zaltenibart's Phase 3 program indicate ongoing operational challenges and regulatory uncertainties. The company's long-term viability still heavily relies on successful regulatory approvals and further commercialization or partnering efforts. The overall sentiment is cautious due to these mixed signals.

Positives

• The Asset Purchase and License Agreement (APLA) with Novo Nordisk for zaltenibart is expected to provide $240.0 million in upfront cash upon closing in Q4 2025, significantly improving liquidity.
• The Novo Nordisk APLA also includes potential for $410.0 million in development/approval milestones and up to $1.3 billion in sales-based milestones, plus tiered royalties, offering substantial future revenue streams.
• The narsoplimab BLA resubmission for TA-TMA was accepted by the FDA, and all requested analyses have consistently provided statistically significant support of narsoplimab's benefit.
• The Marketing Authorization Application (MAA) for narsoplimab in TA-TMA has been validated by the European Medicines Agency (EMA), initiating the formal review process.
• Preclinical studies for the OMS527 (PDE7 inhibitor) program for cocaine use disorder have been successfully completed with no safety findings, supporting future clinical development.
• Net cash used in operating activities decreased by $43.6 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• The company maintained unrestricted cash, cash equivalents, and short-term investments above the $25.0 million covenant required by its Credit Agreement.
• Successfully raised $20.3 million net from a registered direct offering and $15.3 million net from an at-the-market (ATM) equity offering during the nine months ended September 30, 2025, with an additional $3.6 million post-quarter end.

Negatives

• Reported a net loss of $30.9 million for the three months ended September 30, 2025, and $89.8 million for the nine months ended September 30, 2025, indicating continued unprofitability.
• Cash, cash equivalents, and short-term investments significantly decreased to $36.1 million as of September 30, 2025, from $86.7 million at December 31, 2024.
• Negative cash flow from operations of $76.3 million for the nine months ended September 30, 2025.
• The PDUFA target action date for narsoplimab BLA was extended from September 25, 2025, to December 26, 2025, delaying potential regulatory approval.
• The Phase 3 clinical development program for zaltenibart in PNH was temporarily paused due to considerations of capital availability.
• Management explicitly stated "substantial doubt with respect to our ability to meet our obligations through one year from the issuance of the Company's condensed consolidated financial statements" without the anticipated Novo Nordisk transaction or other financing.
• Remeasurement adjustments on the OMIDRIA contract royalty asset resulted in a $13.4 million decrease for the three months and a $16.4 million decrease for the nine months ended September 30, 2025, reflecting lower forecasted sales.
• Interest expense, net of remeasurement adjustments, was a negative $13.4 million for the three months and negative $9.7 million for the nine months ended September 30, 2025, primarily due to non-cash remeasurement costs on the OMIDRIA royalty obligation.

Risks

• The Transaction with Novo Nordisk may not close when anticipated, or at all, due to customary closing conditions, including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act).
• A significant delay or failure to close the Novo Nordisk Transaction would materially adversely affect the company's business, financial condition, results of operations, strategic plans, future operating performance, and ultimately, its ability to continue as a going concern.
• There is no guarantee that the FDA or the EMA will complete their respective reviews of narsoplimab within a given timeframe, or that the BLA or MAA will ultimately be approved.
• The company's ability to continue as a going concern is dependent on generating positive cash flow from operations, obtaining additional financing, entering into strategic alliances, and/or selling assets.
• If the ATM facility is needed but inaccessible, the Novo Nordisk Transaction does not close as anticipated, or the company is unable to obtain debt and/or royalty-related financing or partnering funding for narsoplimab, it would have a significant negative impact on financial condition.
• Future royalty and/or milestone receipts are excluded from available capital resources for purposes of determining the company's ability to meet obligations.
• The company may need to further reduce or delay operations and/or implement restructuring activities to manage projected cash requirements.
• A default under the Credit Agreement would constitute a cross-default under the indentures governing the 2026 Notes and 2029 Notes.
• The 2029 Notes are structurally subordinated to all existing and future indebtedness and other liabilities of the company's subsidiaries.
• Changes in valuation assumptions (e.g., stock price, discount rate, volatility) could have a significant impact on the fair value of embedded derivatives on the 2029 Notes and Term Loan.
• The company does not expect to receive the OMIDRIA sales milestone payment ranging between $10.0 million and $27.5 million prior to January 1, 2026.
• The OMIDRIA royalty rate could be reduced to 10% upon certain events, such as OMIDRIA no longer being eligible for separate payment under Medicare Part B or the entry of generic competition.

Future Outlook

The company expects the Asset Purchase and License Agreement (APLA) with Novo Nordisk to close in the fourth quarter of 2025, providing a $240.0 million upfront cash payment. FDA is anticipated to meet the extended PDUFA date of December 26, 2025, for the narsoplimab BLA, and an EMA opinion on the narsoplimab MAA is expected in mid-2026. The clinical in-patient study for OMS527 in cocaine users is targeted for the second half of 2026, pending additional FDA preclinical information. Research and development expenses in Q4 2025 are projected to be comparable to Q3 2025, while selling, general and administrative expenses are expected to be higher due to anticipated narsoplimab launch marketing. Interest and other income for Q4 2025 is expected to be slightly higher due to increased cash balances. The company does not expect to receive the OMIDRIA sales milestone payment prior to January 1, 2026. IND-enabling work for the OncotoX-AML program is ongoing with an estimated timeline to clinical entry of 18-24 months.

Management Comments

• All analyses requested by FDA as part of its review have been consistent with and have provided statistically significant support of narsoplimab's benefit demonstrated in the analyses submitted as part of the BLA resubmission.
• We expect that FDA will meet the extended PDUFA date of December 26, 2025.
• We expect an opinion on the narsoplimab MAA in the EU in mid-2026.
• We have determined temporarily to pause our Phase 3 clinical development program for zaltenibart in PNH in order to prioritize the use of our available capital to other programs.
• The preclinical studies for OMS527, designed with NIDA toxicologists, have been successfully completed with no safety findings and provide drug-interaction safety data in support of the planned in-patient human study in cocaine users.
• The conditions described, exclusive of any potential future activities, including the anticipated closing of the Transaction with Novo Nordisk or receipt of any related potential milestone payments and/or near-term regulatory approval of narsoplimab, raise substantial doubt with respect to our ability to meet our obligations through one year from the issuance of the Company's condensed consolidated financial statements.

Industry Context

Omeros Corporation operates in the biopharmaceutical sector, focusing on immunologic diseases, including complement-mediated diseases, cancers, and addictive/compulsive disorders. The company's development of narsoplimab for TA-TMA targets a rare disease, aligning with orphan drug strategies that often offer regulatory incentives. The Asset Purchase and License Agreement with Novo Nordisk for zaltenibart (a MASP-3 inhibitor) validates the alternative pathway of complement as a significant therapeutic target, attracting interest from major pharmaceutical players. The PDE7 inhibitor program for cocaine use disorder addresses a critical unmet medical need in the addiction space, with grant support from the National Institute on Drug Abuse (NIDA) underscoring its public health importance. The oncology platform (OncotoX-AML) and Targeted Complement Activating Therapy (T-CAT) platform for multidrug-resistant organisms represent innovative approaches in highly competitive and high-need therapeutic areas, positioning the company at the forefront of novel drug development.

Related Party Transactions

• Registered direct offering of common stock to entities managed by Polar Asset Management Partners.
• Exchange of 2026 Notes for 2029 Notes and the Equitization Transaction with a limited number of holders, including two specific holders for the Equitization Transaction.
• Credit Agreement with Athyrium Capital Management, LP and funds managed by Highbridge Capital Management, LLC.
• Sale of OMIDRIA royalties to DRI Healthcare Acquisition LP.

Stakeholder Impact

• Shareholders face potential for significant dilution from recent and future equity offerings, but also potential for value creation from the Novo Nordisk deal and narsoplimab approval. However, the 'going concern' doubt and PDUFA delay introduce considerable risk.
• Employees may be impacted by potential restructuring activities and delays in clinical programs, which could affect job security or project focus.
• Future customers could benefit from new treatment options for serious diseases if narsoplimab and zaltenibart receive regulatory approvals and are commercialized.
• Creditors, including 2026/2029 Note holders and Term Loan lenders, will see improved debt repayment prospects with the anticipated Novo Nordisk upfront payment, but the underlying 'going concern' risk remains a concern.
• Partners like Novo Nordisk and NIDA are engaged in collaborations that indicate continued development and potential for successful outcomes in their respective programs.

Next Steps

• Closing of the Asset Purchase and License Agreement (APLA) with Novo Nordisk in Q4 2025.
• Mandatory repayment of all outstanding obligations under the Credit Agreement upon closing of the Novo Nordisk transaction.
• FDA decision on narsoplimab BLA by December 26, 2025.
• EMA opinion on narsoplimab MAA in mid-2026.
• Transition of zaltenibart clinical programs to Novo Nordisk following the APLA closing.
• Initiation of clinical in-patient study for OMS527 in cocaine users targeted for H2 2026, pending additional FDA preclinical information.
• Continued preclinical studies for the oncology program (OncotoX-AML) with an estimated timeline to clinical entry of 18-24 months.
• Potential further reduction or delay of operations and/or restructuring activities if needed to manage cash.
• Potential pursuit of public/private equity offerings, debt financings, future royalty sales, or other strategic transactions to raise capital.

Key Dates

Recommendation

The significant upfront payment from the Novo Nordisk deal provides a critical liquidity injection and reduces immediate debt concerns, mitigating the 'going concern' risk. This deal also validates the company's MASP-3 program. However, the PDUFA extension for narsoplimab, continued net losses, and the temporary pause of zaltenibart's Phase 3 program indicate ongoing operational challenges and regulatory uncertainties. The company's long-term viability still heavily relies on successful regulatory approvals and further commercialization or partnering efforts. Given the mixed signals, a 'hold' recommendation is appropriate as investors await the closing of the Novo Nordisk transaction and the FDA decision on narsoplimab.

Keywords

Biopharmaceutical, Clinical-stage, SEC 10-Q, Narsoplimab, TA-TMA, Zaltenibart, MASP-3, MASP-2, Novo Nordisk, Asset Purchase Agreement, BLA, MAA, PDUFA, Orphan indications, Complement system, PDE7 inhibitor, Oncology, Liquidity, Debt, Convertible notes, ATM offering, Registered direct offering, Going concern